Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REPRISE EDGE: REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE Valve System - Evaluation of Performance and Safety

NCT02854319 is registered in ClinicalTrials.gov with Boston Scientific Corporation as lead sponsor.

NCT NCT02854319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02854319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REPRISE EDGE: REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE Valve System - Evaluation of Performance and Safety
Lead sponsor
Boston Scientific Corporation
Phase
Not applicable
Overall status
Terminated
Start date
September 7, 2016
Completion date
March 13, 2018
Enrollment
15 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

aortic valve stenosis